F–star Therapeutics is a biopharmaceutical company focused on developing immuno-oncology bispecific antibody therapeutics. The antibodies specialist won the Life Science Innovation category at the March 2017 Business Weekly Awards.
The company is poised to dominate the bispecific antibody space in immuno-oncology through the application of highly efficient Modular Antibody Technology™ platform. This powerful platform enables the discovery of novel bispecific antibodies, which are selected for their potential to transform the treatment of cancer.
F-star has built a comprehensive IP estate around its technology and product pipeline, with over 350 granted patents and more than 70 pending applications. F-star’s management team has a well-established track record in building biotech companies, and developing biologics. The team is advised by a talented scientific advisory board and a highly experienced board of directors.
F-star Therapeutics stirred speculation of an upcoming US IPO in June 2019 with two major hires and the opening of key operations in the Massachusetts biotech cluster. F-star currently employs over 110 people across the two operations.
F-star is a private company and has successfully raised $56 million in venture capital and public funding.It is backed by Venture Capital investors: Aescap Venture, Atlas Venture, Novo Ventures, and TVM Capital; as well as corporate investors: MS Ventures, MP Healthcare Venture Management, and SR One.